Drug intelligence / Profile preview

M511

Development stage: Preclinical
Lead developer: Johnson & Johnson

Overview

M511 is a drug candidate that was being developed for cancer as part of a biosimilar pipeline. It was part of a collaboration between Baxter and Momenta Pharmaceuticals, initiated in 2011, aimed at expanding Baxter's biosimilar portfolio. Specific details regarding its mechanism of action or the reference biologic it is a biosimilar of are not publicly available.

Beyond the preview

Go deeper on M511.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M511.

Explore the full profile